NCT03862833View on ClinicalTrials.gov

Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

August 29, 2023

Study Completion Date

August 29, 2023

Conditions
Hematopoietic Stem Cell Transplantation
Interventions
DRUG

IL2

"Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40"

DRUG

Zoledronic Acid

4 mg at day +15 post graft

Trial Locations (1)

Unknown

Nantes Uh, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT03862833 - Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant | Biotech Hunter | Biotech Hunter